Myelodysplastic Syndrome (MDS), Flow Cytometry, Bone Marrow
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). The condition primarily affects older adults and presents with fatigue, infection, and bleeding, corresponding to anemia, neutropenia, and thrombocytopenia. MDS arises from genetic and epigenetic alterations that disrupt normal myeloid differentiation and proliferation. These changes, coupled with cytogenetic abnormalities and immune-mediated mechanisms, contribute to disease heterogeneity.
Accurate diagnosis and risk stratification require integration of morphologic, cytogenetic, molecular, and immunophenotypic data. Flow cytometry (FCM), particularly multiparameter flow cytometry (MFC), has become a critical diagnostic tool for MDS. It detects abnormal immunophenotypic patterns, including loss or dim expression of lineage markers, aberrant antigen expression, and disordered maturation, which may not be evident on morphology alone. By analyzing granulocytic, monocytic, erythroid, and lymphoid lineages, FCM enables recognition of clonal hematopoiesis and quantification of dysplastic populations with high sensitivity.
When integrated with morphological and molecular data, flow cytometric findings enhance diagnostic precision and facilitate classification according to current WHO and ICC criteria. FCM is also useful for monitoring disease progression, assessing treatment response, and distinguishing MDS from other causes of cytopenia, such as aplastic anemia or nutritional deficiencies. In contemporary hematopathology, the combination of morphology, cytogenetics, next-generation sequencing (NGS), and flow cytometry has become essential for accurate diagnosis, risk assessment, and personalized management of MDS.
- Aids in diagnosis and classification of MDS by identifying abnormal immunophenotypic profiles
- Assists in prognostication through quantification of aberrant populations and blast percentages
- Monitors disease progression and therapeutic response, especially in high-risk or treated patients
- Differentiates MDS from reactive or secondary causes of cytopenia
Normal Bone Marrow: Balanced expression of lineage-specific markers; no abnormal antigen patterns.
MDS: Aberrant immunophenotypes including:
- Loss or dim expression of lineage markers (e.g., CD13, CD33, CD117).
- Abnormal expression of markers outside normal lineage (e.g., CD7 on myeloid cells).
- Altered maturation patterns in granulocytic or monocytic series.
- Increased or dysregulated blast populations.Interpretation requires correlation with morphology, cytogenetics, and molecular studies.
Negative for cell markers specific to MDS
Bone marrow aspirate collected in EDTA or heparin tubes.
Stability
- Ambient: preferred (process within 24 hours to maintain cell viability)
- Avoid refrigeration unless short-term.
- Nat Rev Dis Primers. 2022 Nov 17;8(1):74. [PMID: 36396662]
- Cytometry B Clin Cytom. 2023 Jan;104(1):27-50. [PMID: 36537621]
- Front Oncol. 2017 Nov 15;7:270. [PMID: 29188193]
- Ann N Y Acad Sci. 2006 Nov;1089:383-94. [PMID: 17261782]
- Cytometry B Clin Cytom. 2023 Jan;104(1):27-50. [PMID: 36537621]